Leeds, UK – Personalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found. The trial, by the University of Leeds, has been identified as groundbreaking research by the New England Journal of Medicine and the...
treatment News
Baltimore MD – A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology. An early phase randomized clinical trial involving 130 patients with sickle cell disease found that...
MIAMI, FLORIDA – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers. Their findings, published in the journal Science,...
Ann Arbor, Mich. – Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s disease. Michigan Medicine researchers confirmed this finding using prospective data. The resulting paper, “Early tumour necrosis factor antagonist treatment prevents perianal...
Ottawa, Canada – Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It’s aggressive and incurable. Even with treatment including surgical removal and chemotherapy, the median survival for patients is just 18 months. Now, innovative new research led by Dr. Arezu Jahani-Asl, Canada Research Chair in Neurobiology of...
PITTSBURGH, PA – A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in macaque monkeys, suggests new University of Pittsburgh research published today in Nature Microbiology. The in-built safety mechanisms circumvent the possibility of an accidental self-infection with weakened mycobacteria, offering a safe and effective way...
Houston, Texas – Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center. After treatment...
SAN FRANCISCO, Calif. — Unlearn®, a leader in AI-powered solutions for clinical trials, today announced a collaboration with Trace Neuroscience, a biotechnology company focused on developing genomic therapies for neurodegenerative diseases. The partnership will support Trace Neuroscience as the company plans its upcoming Phase 1/2 clinical trial in amyotrophic lateral...
PITTSBURGH, Pennsylvania, and JERUSALEM, Israel — The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell – Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the...
AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of...